Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform

News
Multimedia
Publication
Conferences
Resources
Subscribe
Webcasts
Event Calendar

Spotlight -

Downstream Processing|

Upstream Processing

Biopharma Insights-Thought Leadership from Marketers | Sponsored Content | Cygnus Technologies

inSPECt™ MS – Global HCP Profiling and Quantification by Native Digestion and LC-MS Analysis

ByTimothy Licknack,Johanna Barnhill,Stephen Stahlschmidt,Jared Isaac,Brinkley Thornton

April 15th 2026

Best Practices for Quantification of Residual Host Cell DNA with Real-time PCR

ByJenna Frame, PhD, Product Marketing Manager, Cygnus Technologies,Eric Bishop, Vice President, R&D, Cygnus Technologies

February 25th 2025

Antibody Affinity Extraction Outperforms Native Digestion as a Sample Preparation Method for LC-MS Detection of Host Cell Proteins in Drug Substances

ByAlla Zilberman, Vice President, Technical Marketing, Cygnus Technologies, LLC ,Darren Bertin,Stephen Stahlschmidt,Johanna Barnhill,Timothy Licknack,Jared Isaac

May 20th 2024

Predicting Retroviral Particle Clearance with MockV® Retrovirus-like Particles

ByAlla Zilberman, Vice President, Technical Marketing, Cygnus Technologies, LLC ,David Cetlin, Senior Director, MockV Products, Cygnus Technologies, LLC

February 17th 2023

Biopharma Insights - Thought Leadership from Marketers | Paid Program

AAE-MS™ as an Orthogonal Method in Host Cell Protein Analytics

ByAlla Zilberman, Vice President, Technical Marketing, Cygnus Technologies, LLC

May 17th 2022

Biopharma Insights - Thought Leadership from Marketers | Paid Program

HCP ELISA and HCP Antibody Coverage Analysis Methods

ByAlla Zilberman, Biopharma Insights Contributor, Vice President, Technical Marketing, Cygnus Technologies

April 5th 2021

Biopharma Insights - Thought Leadership from Marketers | Paid Program

Predicting Viral Clearance at Your Benchtop

ByDavid Cetlin, Biopharma Insights Contributor, Senior Director of R&D at Cygnus Technologies

July 27th 2020

Biopharma Insights - Thought Leadership from Marketers | Paid Program

Viral contamination is an inherent risk during the manufacture of therapeutic products such as antibodies, vaccines, viral vectors, and plasma derivates.

Trending on BioPharm International

AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide

Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions

Efinopegdutide Meets Primary Endpoint in Phase 2b MASH Trial

FDA Grants RMAT and Fast Track Designations to AbelZeta’s Bispecific CAR-T Prizlon-cel in Large B-Cell Lymphoma